Floatz logo

Personalized Neoantigen Tumor Vaccine

Pancreatic Adenocarcinoma

Ruijin HospitalvaccineEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

189 Active assets in the Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Capecitabine
Zhejiang University
Phase 4BB

View all 50 →

Same molecule, other indications

Personalized Neoantigen Tumor Vaccine is also rated in:

B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
Chemotherapy-intolerantDormant
C
Indicative ·
39 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →